I just read Feuerstein’s piece saying that VRUS might owe royalties to IDIX on its nuke IP, and I think there’s no substance to it. But this has nothing to do with the looming competition from ABT in all-oral HCV cocktails, which is presumably the reason for VRUS’ selloff today.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.